Login to Your Account



Investors Step Up for PTC's $30M Round for DMD Trials

By Catherine Shaffer
Staff Writer

Tuesday, July 24, 2012
Following encouraging results from a Phase III trial, PTC Therapeutics Inc., of South Plainfield, N.J., completed a $30 million financing to support late-stage development of ataluren. The drug has showed clinically meaningful trends in Duchenne's and Becker muscular dystrophy and cystic fibrosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription